Participants
The clinical research protocol was approved by the National Cheng Kung
University Hospital Institutional Review Board (Protocol No.
A-ER-108-119). The study was performed in accordance with the
Declaration of Helsinki. The requirement for informed consent was waived
due to the retrospective nature of the study. The study flow chart
regarding patient inclusion is illustrated in Figure S1 .
Patients with histologically proven EOC/TC/PPC were considered eligible
if they received front-line platinum-based chemotherapy as preoperative
(neoadjuvant) or postoperative (adjuvant) therapy (Cohort 1) or if their
relapsed diseases were treated with BEV ± any chemotherapy (Cohort 2)
between January 1, 2011 and August 31, 2019.
Medical records were reviewed for patients’ clinical characteristics,
treatment-related AEs, and treatment outcomes. Patients without
postoperative front-line chemotherapy owing to any reason and those who
had non-paclitaxel-platinum doublet were excluded. Cancer stage was
determined according to the criteria of the International Federation of
Gynecology and Obstetrics (FIGO). Residual nodules <1 cm and
≥1 cm were categorised as “optimal” and “suboptimal,” respectively.
Cancer progression was defined based on the objective Response
Evaluation Criteria in Solid Tumors 1.1 or the Gynecologic Cancer
InterGroup (GCIG) definition. The last record was retrieved on August
31, 2019. AE severity was graded according to the Common Terminology
Criteria for Adverse Events, version 4.03. OS was calculated based on
the diagnosis date. PFS and PFI were determined using the date of last
contact or progression after front-line chemotherapy. PFI <6
months (m) and ≥6 m were categorized as “platinum-resistant” and
“platinum-sensitive,” respectively. “PFS2-PFS” was calculated based
on the date of the first relapse or persistence to the next progression
or death.